| 
            
              US4401820A
              (en)
            
            
            
           | 
          1981-01-23 | 
          1983-08-30 | 
          Tanabe Seiyaku Co., Ltd. | 
          Process for racemizing optically active α-amino acids or a salt thereof 
        | 
        
        
          | 
            
              US4816567A
              (en)
            
            
            
           | 
          1983-04-08 | 
          1989-03-28 | 
          Genentech, Inc. | 
          Recombinant immunoglobin preparations 
        | 
        
        
          | 
            
              US5262296A
              (en)
            
            
            
           | 
          1988-03-30 | 
          1993-11-16 | 
          Toray Industries, Inc. | 
          Freeze-dried composition containing enzyme-labeled anti-human interferon-β antibody and enzyme immunoassay kit containing the composition 
        | 
        
        
          | 
            
              DE68908175T2
              (de)
            
            
            
           | 
          1988-05-27 | 
          1994-03-03 | 
          Centocor Inc | 
          Gefriergetrocknete formulierung für antikörperprodukte. 
        | 
        
        
          | 
            
              ES2191016T3
              (es)
            
            
            
           | 
          1992-09-16 | 
          2003-09-01 | 
          Scripps Research Inst | 
          Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial. 
        | 
        
        
          | 
            
              DK2275119T3
              (da)
            
            
            
           | 
          1995-07-27 | 
          2013-11-11 | 
          Genentech Inc | 
          Stabil, isotonisk lyofiliseret proteinformulering 
        | 
        
        
          | 
            
              US6267958B1
              (en)
            
            
            
           | 
          1995-07-27 | 
          2001-07-31 | 
          Genentech, Inc. | 
          Protein formulation 
        | 
        
        
          | 
            
              WO1997010846A1
              (en)
            
            
            
           | 
          1995-09-18 | 
          1997-03-27 | 
          Intracel Corporation | 
          Neutralizing monoclonal antibodies to respiratory syncytial virus 
        | 
        
        
          | 
            
              US7365166B2
              (en)
            
            
            
           | 
          1997-04-07 | 
          2008-04-29 | 
          Genentech, Inc. | 
          Anti-VEGF antibodies 
        | 
        
        
          | 
            
              US6171586B1
              (en)
            
            
            
           | 
          1997-06-13 | 
          2001-01-09 | 
          Genentech, Inc. | 
          Antibody formulation 
        | 
        
        
          | 
            
              HK1044159A1
              (zh)
            
            
            
           | 
          1998-12-01 | 
          2002-10-11 | 
          蛋白质设计实验室股份有限公司 | 
          抗γ-干扰素的人化抗体 
      | 
        
        
          | 
            
              WO2000048635A1
              (en)
            
            
            
           | 
          1999-02-22 | 
          2000-08-24 | 
          Baxter International Inc. | 
          Novel albumin-free factor viii formulations 
        | 
        
        
          | 
            
              WO2000053631A1
              (en)
            
            
            
           | 
          1999-03-11 | 
          2000-09-14 | 
          Schering Corporation | 
          Mammalian cytokines; related reagents and methods 
        | 
        
        
          | 
            
              JP4505166B2
              (ja)
            
            
            
           | 
          1999-09-09 | 
          2010-07-21 | 
          シェーリング  コーポレイション | 
          哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用 
        | 
        
        
          | 
            
              US7090847B1
              (en)
            
            
            
           | 
          1999-09-09 | 
          2006-08-15 | 
          Schering Corporation | 
          Mammalian cytokines; related reagents and methods 
        | 
        
        
          | 
            
              AU1102401A
              (en)
            
            *
            
           | 
          1999-10-22 | 
          2001-05-08 | 
          Ludwig Institute For Cancer Research | 
          Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products 
      | 
        
        
          | 
            
              US20050175986A1
              (en)
            
            
            
           | 
          2000-05-09 | 
          2005-08-11 | 
          Smit Kline Beecham Corporation | 
          Human monoclonal antibody 
        | 
        
        
          | 
            
              ATE442862T2
              (de)
            
            
            
           | 
          2000-10-12 | 
          2009-10-15 | 
          Genentech Inc | 
          Niederviskose konzentrierte proteinformulierungen 
        | 
        
        
          | 
            
              US8703126B2
              (en)
            
            
            
           | 
          2000-10-12 | 
          2014-04-22 | 
          Genentech, Inc. | 
          Reduced-viscosity concentrated protein formulations 
        | 
        
        
          | 
            
              US6818216B2
              (en)
            
            
            
           | 
          2000-11-28 | 
          2004-11-16 | 
          Medimmune, Inc. | 
          Anti-RSV antibodies 
        | 
        
        
          | 
            
              EP1801123A3
              (en)
            
            
            
           | 
          2000-12-28 | 
          2007-11-21 | 
          Altus Pharmaceuticals Inc. | 
          Crystals of whole antibodies and fragments thereof and methods for making and using them 
        | 
        
        
          | 
            
              WO2002072636A2
              (en)
            
            
            
           | 
          2000-12-28 | 
          2002-09-19 | 
          Altus Biologics Inc. | 
          Crystals of whole antibodies and fragments thereof and methods for making and using them 
        | 
        
        
          | 
            
              GB0113179D0
              (en)
            
            
            
           | 
          2001-05-31 | 
          2001-07-25 | 
          Novartis Ag | 
          Organic compounds 
      | 
        
        
          | 
            
              CA2451185A1
              (en)
            
            
            
           | 
          2001-06-21 | 
          2003-01-03 | 
          Altus Biologics, Inc. | 
          Spherical protein particles and methods of making and using them 
      | 
        
        
          | 
            
              DE60235989D1
              (de)
            
            
            
           | 
          2001-06-26 | 
          2010-05-27 | 
          Amgen Fremont Inc | 
          Antikörper gegen opgl 
        | 
        
        
          | 
            
              ATE454137T1
              (de)
            
            
            
           | 
          2001-07-25 | 
          2010-01-15 | 
          Facet Biotech Corp | 
          Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab 
        | 
        
        
          | 
            
              DK1441589T3
              (da)
            
            
            
           | 
          2001-11-08 | 
          2012-08-06 | 
          Abbott Biotherapeutics Corp | 
          Stabil, flydende, farmaceutisk sammensætning af IgG-antistoffer 
        | 
        
        
          | 
            
              DE10207178A1
              (de)
            
            
            
           | 
          2002-02-19 | 
          2003-09-04 | 
          Novosom Ag | 
          Komponenten für die Herstellung amphoterer Liposomen 
        | 
        
        
          | 
            
              SI1478394T1
              (sl)
            
            
            
           | 
          2002-02-27 | 
          2008-12-31 | 
          Immunex Corp | 
          STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM 
        | 
        
        
          | 
            
              WO2003086310A2
              (en)
            
            
            
           | 
          2002-04-12 | 
          2003-10-23 | 
          Ramot At Tel Aviv University Ltd. | 
          Prevention of brain inflammation as a result of induced autoimmune response 
        | 
        
        
          | 
            
              US7132100B2
              (en)
            
            
            
           | 
          2002-06-14 | 
          2006-11-07 | 
          Medimmune, Inc. | 
          Stabilized liquid anti-RSV antibody formulations 
        | 
        
        
          | 
            
              DK2206517T3
              (da)
            
            
            
           | 
          2002-07-03 | 
          2023-11-06 | 
          Ono Pharmaceutical Co | 
          Immunpotentierende sammensætninger omfattende af anti-PD-L1-antistoffer 
        | 
        
        
          | 
            
              JP2006502116A
              (ja)
            
            
            
           | 
          2002-07-12 | 
          2006-01-19 | 
          メダレックス, インク. | 
          タンパク質の酸化分解を防ぐ方法及び組成物 
        | 
        
        
          | 
            
              US20040033228A1
              (en)
            
            
            
           | 
          2002-08-16 | 
          2004-02-19 | 
          Hans-Juergen Krause | 
          Formulation of human antibodies for treating TNF-alpha associated disorders 
      | 
        
        
          | 
            
              AU2003265511A1
              (en)
            
            
            
           | 
          2002-08-21 | 
          2004-03-11 | 
          Pharmacia Corporation | 
          Injectable pharmaceutical suspension in a two-chamber vial 
      | 
        
        
          | 
            
              WO2004019861A2
              (en)
            
            
            
           | 
          2002-08-28 | 
          2004-03-11 | 
          Pharmacia Corporation | 
          Stable ph optimized formulation of a modified antibody 
        | 
        
        
          | 
            
              US20040191243A1
              (en)
            
            
            
           | 
          2002-12-13 | 
          2004-09-30 | 
          Bei Chen | 
          System and method for stabilizing antibodies with histidine 
        | 
        
        
          | 
            
              US7488802B2
              (en)
            
            
            
           | 
          2002-12-23 | 
          2009-02-10 | 
          Wyeth | 
          Antibodies against PD-1 
        | 
        
        
          | 
            
              US7563869B2
              (en)
            
            
            
           | 
          2003-01-23 | 
          2009-07-21 | 
          Ono Pharmaceutical Co., Ltd. | 
          Substance specific to human PD-1 
        | 
        
        
          | 
            
              WO2004071517A2
              (en)
            
            
            
           | 
          2003-02-06 | 
          2004-08-26 | 
          Schering Corporation | 
          Uses of il-23 related reagents 
      | 
        
        
          | 
            
              PT2236154T
              (pt)
            
            
            
           | 
          2003-02-10 | 
          2018-06-26 | 
          Biogen Ma Inc | 
          Formulação de imunoglobulinas e método de preparação das mesmas 
        | 
        
        
          | 
            
              NZ541898A
              (en)
            
            
            
           | 
          2003-03-10 | 
          2008-07-31 | 
          Schering Corp | 
          Uses of IL-23 antagonists for the manufacture of a medicament for the treatment of tumors 
      | 
        
        
          | 
            
              BRPI0403964B8
              (pt)
            
            
            
           | 
          2003-04-04 | 
          2021-05-25 | 
          Genentech Inc | 
          formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige 
        | 
        
        
          | 
            
              JP4703566B2
              (ja)
            
            
            
           | 
          2003-05-14 | 
          2011-06-15 | 
          イムノゲン  インコーポレーティッド | 
          薬剤複合体組成物 
        | 
        
        
          | 
            
              US20070212346A1
              (en)
            
            
            
           | 
          2003-10-09 | 
          2007-09-13 | 
          Tomoyuki Igawa | 
          Highly Concentrated Stabilized Igm Solution 
        | 
        
        
          | 
            
              US8277810B2
              (en)
            
            
            
           | 
          2003-11-04 | 
          2012-10-02 | 
          Novartis Vaccines & Diagnostics, Inc. | 
          Antagonist anti-CD40 antibodies 
        | 
        
        
          | 
            
              PE20050925A1
              (es)
            
            
            
           | 
          2003-11-10 | 
          2005-11-29 | 
          Schering Corp | 
          Anticuerpo recombinante humanizado anti-interleuquina 10 
        | 
        
        
          | 
            
              DE10355904A1
              (de)
            
            
            
           | 
          2003-11-29 | 
          2005-06-30 | 
          Merck Patent Gmbh | 
          Feste Formen von anti-EGFR-Antikörpern 
        | 
        
        
          | 
            
              EP1712240B1
              (en)
            
            
            
           | 
          2003-12-25 | 
          2015-09-09 | 
          Kyowa Hakko Kirin Co., Ltd. | 
          Stable water-based medicinal preparation containing antibody 
        | 
        
        
          | 
            
              NZ548785A
              (en)
            
            
            
           | 
          2004-01-07 | 
          2011-08-26 | 
          Novartis Vaccines & Diagnostic | 
          M-CSF-Specific monoclonal antibody and uses thereof 
      | 
        
        
          | 
            
              CA2555791A1
              (en)
            
            
            
           | 
          2004-02-12 | 
          2005-08-25 | 
          Merck Patent Gesellschaft Mit Beschraenkter Haftung | 
          Highly concentrated liquid formulations of anti-egfr antibodies 
      | 
        
        
          | 
            
              BRPI0507794A
              (pt)
            
            
            
           | 
          2004-02-17 | 
          2007-07-17 | 
          Schering Corp | 
          métodos de modular a atividade de il-23, reagentes relacionados 
        | 
        
        
          | 
            
              US7662384B2
              (en)
            
            
            
           | 
          2004-03-24 | 
          2010-02-16 | 
          Facet Biotech Corporation | 
          Use of anti-α5β1 antibodies to inhibit cancer cell proliferation 
        | 
        
        
          | 
            
              JP4879884B2
              (ja)
            
            
            
           | 
          2004-04-12 | 
          2012-02-22 | 
          メディミューン,エルエルシー | 
          抗−il−9抗体製剤及びその使用法 
        | 
        
        
          | 
            
              WO2005120571A2
              (en)
            
            
            
           | 
          2004-06-07 | 
          2005-12-22 | 
          Ramot At Tel Aviv University Ltd. | 
          Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation 
        | 
        
        
          | 
            
              AR049390A1
              (es)
            
            
            
           | 
          2004-06-09 | 
          2006-07-26 | 
          Wyeth Corp | 
          Anticuerpos contra la interleuquina-13 humana y usos de los mismos 
        | 
        
        
          | 
            
              SG190665A1
              (en)
            
            
            
           | 
          2004-07-30 | 
          2013-06-28 | 
          Rinat Neuroscience Corp | 
          Antibodies directed against amyloid-beta peptide and methods using same 
      | 
        
        
          | 
            
              JO3000B1
              (ar)
            
            
            
           | 
          2004-10-20 | 
          2016-09-05 | 
          Genentech Inc | 
          مركبات أجسام مضادة . 
        | 
        
        
          | 
            
              US20080057070A1
              (en)
            
            
            
           | 
          2004-11-04 | 
          2008-03-06 | 
          Chiron Corporation | 
          Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use 
        | 
        
        
          | 
            
              UY29350A1
              (es)
            
            
            
           | 
          2005-01-28 | 
          2006-08-31 | 
          Wyeth Corp | 
          Formulaciones liquidas estabilizadasde polipeptido 
        | 
        
        
          | 
            
              GT200600031A
              (es)
            
            
            
           | 
          2005-01-28 | 
          2006-08-29 | 
           | 
          Formulacion anticuerpo anti a beta 
        | 
        
        
          | 
            
              DOP2006000029A
              (es)
            
            
            
           | 
          2005-02-07 | 
          2006-08-15 | 
          Genentech Inc | 
          Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) 
        | 
        
        
          | 
            
              EP1871806A2
              (en)
            
            
            
           | 
          2005-03-08 | 
          2008-01-02 | 
          Pharmacia & Upjohn Company LLC | 
          ANTI-MAdCAM ANTIBODY COMPOSITIONS 
        | 
        
        
          | 
            
              US7785595B2
              (en)
            
            
            
           | 
          2005-04-18 | 
          2010-08-31 | 
          Yeda Research And Development Company Limited | 
          Stabilized anti-hepatitis B (HBV) antibody formulations 
        | 
        
        
          | 
            
              BRPI0608376A8
              (pt)
            
            
            
           | 
          2005-04-22 | 
          2018-10-16 | 
          Lilly Co Eli | 
          composição de ligação, método de uso de uma composição de ligação, e, kit de detecção 
        | 
        
        
          | 
            
              CA3151350A1
              (en)
            
            
            
           | 
          2005-05-09 | 
          2006-11-16 | 
          E. R. Squibb & Sons, L.L.C. | 
          Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics 
      | 
        
        
          | 
            
              RU2415151C2
              (ru)
            
            
            
           | 
          2005-06-07 | 
          2011-03-27 | 
          Эсбатек Аг | 
          СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα 
        | 
        
        
          | 
            
              MX2007016306A
              (es)
            
            
            
           | 
          2005-06-15 | 
          2008-03-07 | 
          Schering Corp | 
          Formulaciones de anticuerpo anti-igf1r. 
        | 
        
        
          | 
            
              TR201902033T4
              (tr)
            
            
            
           | 
          2005-06-30 | 
          2019-03-21 | 
          Janssen Biotech Inc | 
          Anti-IL-23 antikorları, bileşimleri, yöntemleri ve kullanımları. 
        | 
        
        
          | 
            
              EP1909838A2
              (en)
            
            
            
           | 
          2005-07-29 | 
          2008-04-16 | 
          Amgen Inc. | 
          Formulations that inhibit protein aggregation 
        | 
        
        
          | 
            
              CA2615122A1
              (en)
            
            
            
           | 
          2005-08-03 | 
          2007-02-15 | 
          Immunogen, Inc. | 
          Immunoconjugate formulations 
        | 
        
        
          | 
            
              DE602006015830D1
              (de)
            
            
            
           | 
          2005-08-25 | 
          2010-09-09 | 
          Lilly Co Eli | 
          Anti-il-23-antikörper 
        | 
        
        
          | 
            
              WO2007027714A2
              (en)
            
            
            
           | 
          2005-08-31 | 
          2007-03-08 | 
          Schering Corporation | 
          Engineered anti-il-23 antibodies 
        | 
        
        
          | 
            
              WO2007033230A2
              (en)
            
            
            
           | 
          2005-09-12 | 
          2007-03-22 | 
          Novimmune S.A. | 
          Anti-cd3 antibody formulations 
        | 
        
        
          | 
            
              PL1942939T5
              (pl)
            
            
            
           | 
          2005-09-30 | 
          2021-10-11 | 
          Medimmune Limited | 
          Kompozycja przeciwciała interleukiny-13 
        | 
        
        
          | 
            
              US9084777B2
              (en)
            
            
            
           | 
          2005-12-28 | 
          2015-07-21 | 
          Chugai Seiyaku Kabushiki Kaisha | 
          Stabilized antibody-containing formulations 
        | 
        
        
          | 
            
              HUE049832T2
              (hu)
            
            
            
           | 
          2005-12-29 | 
          2020-10-28 | 
          Janssen Biotech Inc | 
          Humán anti-IL-23 ellenanyagok, készítmények, eljárás és alkalmazások 
        | 
        
        
          | 
            
              AU2007212147A1
              (en)
            
            
            
           | 
          2006-02-03 | 
          2007-08-16 | 
          Medimmune, Llc | 
          Protein formulations 
      | 
        
        
          | 
            
              KR20080104160A
              (ko)
            
            
            
           | 
          2006-03-28 | 
          2008-12-01 | 
          에프. 호프만-라 로슈 아게 | 
          항-igf-1r 인간 단일클론 항체 제형 
        | 
        
        
          | 
            
              SMP200800064B
              (it)
            
            
            
           | 
          2006-04-21 | 
          2009-11-06 | 
          Novartis Ag | 
          Composizioni farmaceutiche di anticorpi anti-cd40 antagonista 
        | 
        
        
          | 
            
              US20080003220A1
              (en)
            
            
            
           | 
          2006-04-21 | 
          2008-01-03 | 
          Amgen, Inc. | 
          Buffering agents for biopharmaceutical formulations 
        | 
        
        
          | 
            
              CA2655372A1
              (en)
            
            
            
           | 
          2006-06-13 | 
          2007-12-21 | 
          Zymogenetics, Inc. | 
          Il-17 and il-23 antagonists and methods of using the same 
        | 
        
        
          | 
            
              ES2827180T3
              (es)
            
            
            
           | 
          2006-10-06 | 
          2021-05-20 | 
          Amgen Inc | 
          Formulaciones de anticuerpos estables 
        | 
        
        
          | 
            
              CA2666492C
              (en)
            
            
            
           | 
          2006-10-20 | 
          2012-07-17 | 
          Douglas Rehder | 
          Stable polypeptide formulations 
        | 
        
        
          | 
            
              CN104072612A
              (zh)
            
            
            
           | 
          2006-10-27 | 
          2014-10-01 | 
          艾伯维生物技术有限公司 | 
          结晶型抗-hTNFα抗体 
        | 
        
        
          | 
            
              WO2008068246A1
              (en)
            
            
            
           | 
          2006-12-05 | 
          2008-06-12 | 
          Crucell Holland B.V. | 
          Liquid anti-rabies antibody formulations 
        | 
        
        
          | 
            
              AR064333A1
              (es)
            
            
            
           | 
          2006-12-14 | 
          2009-04-01 | 
          Schering Corp | 
          Anticuerpo anti-tslp de diseno 
        | 
        
        
          | 
            
              CA2790018C
              (en)
            
            
            
           | 
          2006-12-21 | 
          2015-02-03 | 
          Amgen Inc. | 
          Formulations 
      | 
        
        
          | 
            
              PE20081610A1
              (es)
            
            
            
           | 
          2007-01-09 | 
          2008-12-09 | 
          Wyeth Corp | 
          Formulaciones de anticuerpos anti-il-13 y usos de los mismos 
        | 
        
        
          | 
            
              TWI426918B
              (zh)
            
            
            
           | 
          2007-02-12 | 
          2014-02-21 | 
          Merck Sharp & Dohme | 
          Il-23拮抗劑於治療感染之用途 
        | 
        
        
          | 
            
              JP2010518858A
              (ja)
            
            
            
           | 
          2007-02-23 | 
          2010-06-03 | 
          シェーリング  コーポレイション | 
          操作された抗−il−23p19抗体 
        | 
        
        
          | 
            
              JP2010518856A
              (ja)
            
            
            
           | 
          2007-02-23 | 
          2010-06-03 | 
          シェーリング  コーポレイション | 
          操作された抗−IL−23p19抗体 
        | 
        
        
          | 
            
              CN101679507A
              (zh)
            
            
            
           | 
          2007-03-29 | 
          2010-03-24 | 
          艾博特公司 | 
          结晶抗人类il-12抗体 
        | 
        
        
          | 
            
              AU2008232903B9
              (en)
            
            
            
           | 
          2007-03-30 | 
          2013-09-05 | 
          Medimmune Llc | 
          Antibodies with decreased deamidation profiles 
        | 
        
        
          | 
            
              US20090208492A1
              (en)
            
            
            
           | 
          2007-06-14 | 
          2009-08-20 | 
          Elan Pharmaceuticals, Inc. | 
          Lyophilized Immunoglobulin Formulations and Methods of Preparation 
        | 
        
        
          | 
            
              EA020456B1
              (ru)
            
            
            
           | 
          2007-06-14 | 
          2014-11-28 | 
          Байоджен Айдек Ма Инк. | 
          Фармацевтическая композиция, содержащая связывающееся с vla-4 антитело, для подкожной или внутримышечной доставки 
        | 
        
        
          | 
            
              CN102131828B
              (zh)
            
            
            
           | 
          2007-06-18 | 
          2015-06-17 | 
          默沙东有限责任公司 | 
          针对人程序性死亡受体pd-1的抗体 
        | 
        
        
          | 
            
              JP5513380B2
              (ja)
            
            
            
           | 
          2007-06-25 | 
          2014-06-04 | 
          アムジエン・インコーポレーテツド | 
          肝細胞増殖因子に対する特異的結合剤の組成物 
        | 
        
        
          | 
            
              UA107557C2
              (xx)
            
            
            
           | 
          2007-07-06 | 
          2015-01-26 | 
           | 
          Композиція антитіла офатумумабу 
        | 
        
        
          | 
            
              US20100286038A1
              (en)
            
            
            
           | 
          2007-09-21 | 
          2010-11-11 | 
          Valentyn Antochshuk | 
          Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same 
        | 
        
        
          | 
            
              EP2205276A4
              (en)
            
            
            
           | 
          2007-09-28 | 
          2012-08-15 | 
          Janssen Biotech Inc | 
          
  ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES
 
        | 
        
        
          | 
            
              AR068723A1
              (es)
            
            
            
           | 
          2007-10-05 | 
          2009-12-02 | 
          Glaxo Group Ltd | 
          Proteina que se une a antigenos que se une a il-23 humana y sus usos 
        | 
        
        
          | 
            
              WO2009070642A1
              (en)
            
            
            
           | 
          2007-11-28 | 
          2009-06-04 | 
          Medimmune, Llc | 
          Protein formulation 
        | 
        
        
          | 
            
              JP5881950B2
              (ja)
            
            
            
           | 
          2007-12-21 | 
          2016-03-09 | 
          エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 
          抗体処方物 
        | 
        
        
          | 
            
              PE20091174A1
              (es)
            
            
            
           | 
          2007-12-27 | 
          2009-08-03 | 
          Chugai Pharmaceutical Co Ltd | 
          Formulacion liquida con contenido de alta concentracion de anticuerpo 
        | 
        
        
          | 
            
              BRPI0821600A2
              (pt)
            
            
            
           | 
          2007-12-28 | 
          2015-06-23 | 
          Bioinvent Int Ab | 
          Composição farmacêutica, artigo de fabricação, kit de partes, método de combater aterosclerose, ou uma doença cardiovascular associada à aterosclerose, e, uso de um anticorpo 
        | 
        
        
          | 
            
              EA201001223A1
              (ru)
            
            
            
           | 
          2008-02-07 | 
          2011-06-30 | 
          Эмджен Инк. | 
          Стабилизированные белковые композиции 
        | 
        
        
          | 
            
              CN101970499B
              (zh)
            
            
            
           | 
          2008-02-11 | 
          2014-12-31 | 
          治疗科技公司 | 
          用于肿瘤治疗的单克隆抗体 
        | 
        
        
          | 
            
              WO2009120684A1
              (en)
            
            
            
           | 
          2008-03-25 | 
          2009-10-01 | 
          Medimmune, Llc | 
          Antibody formulation 
        | 
        
        
          | 
            
              CN110082533B
              (zh)
            
            
            
           | 
          2008-04-09 | 
          2023-01-10 | 
          健泰科生物技术公司 | 
          用于免疫相关疾病的治疗的新组合物和方法 
        | 
        
        
          | 
            
              RU2010153580A
              (ru)
            
            
            
           | 
          2008-06-03 | 
          2012-07-20 | 
          Эбботт Лэборетриз (Us) | 
          Иммуноглобулины с двумя вариабельными доменами и их применение 
        | 
        
        
          | 
            
              JP5945096B2
              (ja)
            
            
            
           | 
          2008-07-04 | 
          2016-07-05 | 
          小野薬品工業株式会社 | 
          抗ヒトpd−1抗体の癌に対する治療効果を最適化するための判定マーカーの使用 
        | 
        
        
          | 
            
              CA2734919C
              (en)
            
            
            
           | 
          2008-08-27 | 
          2016-08-16 | 
          Schering Corporation | 
          Lyophilized formulations of engineered anti-il-23p19 antibodies 
      | 
        
        
          | 
            
              WO2010032220A1
              (en)
            
            
            
           | 
          2008-09-19 | 
          2010-03-25 | 
          Pfizer Inc. | 
          Stable liquid antibody formulation 
        | 
        
        
          | 
            
              MX345226B
              (es)
            
            
            
           | 
          2008-10-29 | 
          2017-01-20 | 
          Ablynx Nv | 
          Formulaciones de moleculas de union a antigeno de dominio sencillo. 
        | 
        
        
          | 
            
              WO2010062372A2
              (en)
            
            
            
           | 
          2008-11-03 | 
          2010-06-03 | 
          President And Fellows Of Harvard College | 
          Methods for modulating nf-kb using gibberellins 
        | 
        
        
          | 
            
              PE20120204A1
              (es)
            
            
            
           | 
          2008-11-17 | 
          2012-03-03 | 
          Genentech Inc | 
          Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas 
        | 
        
        
          | 
            
              WO2010069858A1
              (en)
            
            
            
           | 
          2008-12-19 | 
          2010-06-24 | 
          F. Hoffmann-La Roche Ag | 
          Pharmaceutical composition 
        | 
        
        
          | 
            
              AR075715A1
              (es)
            
            
            
           | 
          2009-03-05 | 
          2011-04-20 | 
          Novartis Ag | 
          Formulacion de anticuerpo liofilizado 
        | 
        
        
          | 
            
              JP2012519706A
              (ja)
            
            
            
           | 
          2009-03-06 | 
          2012-08-30 | 
          ジェネンテック,  インコーポレイテッド | 
          抗体製剤 
        | 
        
        
          | 
            
              MX2011009312A
              (es)
            
            
            
           | 
          2009-03-06 | 
          2012-02-29 | 
          Medimmune Llc | 
          Formulaciones de anticuerpos humanizados anti-cd19. 
        | 
        
        
          | 
            
              EP2230312A1
              (en)
            
            
            
           | 
          2009-03-19 | 
          2010-09-22 | 
          Helmholtz-Zentrum für Infektionsforschung GmbH | 
          Probe compound for detecting and isolating enzymes and means and methods using the same 
        | 
        
        
          | 
            
              CN102458469B
              (zh)
            
            
            
           | 
          2009-05-04 | 
          2014-12-24 | 
          艾伯维生物技术有限公司 | 
          人抗TNF-α抗体的稳定高蛋白质浓度制剂 
        | 
        
        
          | 
            
              US9155745B2
              (en)
            
            
            
           | 
          2009-06-16 | 
          2015-10-13 | 
          Universite De Geneve | 
          Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs 
        | 
        
        
          | 
            
              AU2010263058A1
              (en)
            
            
            
           | 
          2009-06-18 | 
          2012-01-12 | 
          Wyeth Llc | 
          Lyophilized formulations for small modular immunopharmaceuticals 
      | 
        
        
          | 
            
              CA2765220A1
              (en)
            
            
            
           | 
          2009-07-14 | 
          2011-01-20 | 
          Biogen Idec Ma Inc. | 
          Methods for inhibiting yellow color and peroxide formation in a composition 
      | 
        
        
          | 
            
              WO2011017070A1
              (en)
            
            
            
           | 
          2009-07-28 | 
          2011-02-10 | 
          Merck Sharp & Dohme Corp. | 
          Methods for producing high concentration lyophilized pharmaceutical formulations 
        | 
        
        
          | 
            
              US9345661B2
              (en)
            
            
            
           | 
          2009-07-31 | 
          2016-05-24 | 
          Genentech, Inc. | 
          Subcutaneous anti-HER2 antibody formulations and uses thereof 
        | 
        
        
          | 
            
              WO2011024862A1
              (ja)
            
            
            
           | 
          2009-08-31 | 
          2011-03-03 | 
          三洋化成工業株式会社 | 
          タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及び液体洗剤組成物、並びに、この安定化剤を用いるタンパク質の安定化方法 
        | 
        
        
          | 
            
              ES2788869T3
              (es)
            
            
            
           | 
          2009-09-03 | 
          2020-10-23 | 
          Merck Sharp & Dohme | 
          Anticuerpos anti-GITR 
        | 
        
        
          | 
            
              EP2473191B1
              (en)
            
            
            
           | 
          2009-09-04 | 
          2017-08-23 | 
          XOMA Technology Ltd. | 
          Antibody coformulations 
        | 
        
        
          | 
            
              AR078161A1
              (es)
            
            
            
           | 
          2009-09-11 | 
          2011-10-19 | 
          Hoffmann La Roche | 
          Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. 
        | 
        
        
          | 
            
              PE20121646A1
              (es)
            
            
            
           | 
          2009-11-04 | 
          2012-12-02 | 
          Merck Sharp & Dohme | 
          Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica 
        | 
        
        
          | 
            
              RU2609658C2
              (ru)
            
            
            
           | 
          2009-12-21 | 
          2017-02-02 | 
          Дженентек, Инк. | 
          Состав, содержащий антитело 
        | 
        
        
          | 
            
              JP2013515754A
              (ja)
            
            
            
           | 
          2009-12-29 | 
          2013-05-09 | 
          エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 
          新規な抗体製剤 
        | 
        
        
          | 
            
              US20120294866A1
              (en)
            
            
            
           | 
          2010-01-19 | 
          2012-11-22 | 
          F. Hoffmann-La Roche Ag | 
          Pharmaceutical formulation for proteins 
      | 
        
        
          | 
            
              AR080428A1
              (es)
            
            
            
           | 
          2010-01-20 | 
          2012-04-11 | 
          Chugai Pharmaceutical Co Ltd | 
          Formulaciones liquidas estabilizadas contentivas de anticuerpos 
        | 
        
        
          | 
            
              WO2011116090A1
              (en)
            
            
            
           | 
          2010-03-17 | 
          2011-09-22 | 
          Abbott Research B.V. | 
          Anti-nerve growth factor (ngf) antibody compositions 
        | 
        
        
          | 
            
              CN102958538A
              (zh)
            
            
            
           | 
          2010-05-03 | 
          2013-03-06 | 
          弗·哈夫曼-拉罗切有限公司 | 
          用于降低含有蛋白质的制剂的粘度的组合物和方法 
        | 
        
        
          | 
            
              CN103402516B
              (zh)
            
            
            
           | 
          2010-06-17 | 
          2018-01-30 | 
          富津世生物技术有限公司 | 
          用作抗病毒药物的化合物、组合物及使用方法 
        | 
        
        
          | 
            
              EP2399604A1
              (en)
            
            
            
           | 
          2010-06-25 | 
          2011-12-28 | 
          F. Hoffmann-La Roche AG | 
          Novel antibody formulation 
        | 
        
        
          | 
            
              FR2962908A1
              (fr)
            
            
            
           | 
          2010-07-20 | 
          2012-01-27 | 
          Lfb Biotechnologies | 
          Formulation d'anticorps anti-cd20 
        | 
        
        
          | 
            
              WO2012018538A2
              (en)
            
            
            
           | 
          2010-07-26 | 
          2012-02-09 | 
          Schering Corporation | 
          Bioassays for determining pd-1 modulation 
        | 
        
        
          | 
            
              PH12013500672A1
              (en)
            
            
            
           | 
          2010-10-06 | 
          2013-06-03 | 
          Regeneron Pharma | 
          Stabilized formulations containing anti-interleukin-4-receptor (il-4r) antibodies 
      | 
        
        
          | 
            
              US9458240B2
              (en)
            
            
            
           | 
          2010-12-10 | 
          2016-10-04 | 
          Novartis Pharma Ag | 
          Anti-BAFFR antibody formulations 
        | 
        
        
          | 
            
              US9145457B2
              (en)
            
            
            
           | 
          2011-03-25 | 
          2015-09-29 | 
          Amgen Inc. | 
          Sclerostin antibody crystals and formulations thereof 
        | 
        
        
          | 
            
              CA2830806C
              (en)
            
            *
            
           | 
          2011-03-31 | 
          2020-05-12 | 
          Merck Sharp & Dohme Corp. | 
          Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments 
        | 
        
        
          | 
            
              EP2694708A4
              (en)
            
            
            
           | 
          2011-04-07 | 
          2014-10-01 | 
          Glaxosmithkline Llc | 
          
        FORMULATIONS WITH REDUCED VISCOSITY
       
        | 
        
        
          | 
            
              UY34105A
              (es)
            
            
            
           | 
          2011-06-03 | 
          2012-07-31 | 
          Lg Life Sciences Ltd | 
          Formulación líquida estable de etanercept 
        | 
        
        
          | 
            
              EP2735315B1
              (en)
            
            
            
           | 
          2011-07-19 | 
          2019-10-02 | 
          Chugai Seiyaku Kabushiki Kaisha | 
          Stable protein-containing preparation containing argininamide or valinamide 
        | 
        
        
          | 
            
              AR087305A1
              (es)
            
            
            
           | 
          2011-07-28 | 
          2014-03-12 | 
          Regeneron Pharma | 
          Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit 
        | 
        
        
          | 
            
              WO2013063468A1
              (en)
            
            
            
           | 
          2011-10-27 | 
          2013-05-02 | 
          Massachusetts Institute Of Technology | 
          Amino acid derivates functionalized on the n- terminal capable of forming drug incapsulating microspheres 
        | 
        
        
          | 
            
              WO2013112438A1
              (en)
            
            
            
           | 
          2012-01-23 | 
          2013-08-01 | 
          Regeneron Pharmaceuticals, Inc. | 
          Stabilized formulations containing anti-ang2 antibodies 
        | 
        
        
          | 
            
              CN104159614A
              (zh)
            
            
            
           | 
          2012-03-07 | 
          2014-11-19 | 
          卡迪拉保健有限公司 | 
          TNF-α抗体的药物制剂 
        | 
        
        
          | 
            
              WO2013150273A1
              (en)
            
            
            
           | 
          2012-04-03 | 
          2013-10-10 | 
          University Court Of The University Of St Andrews | 
          High resolution imaging of extended volumes 
        | 
        
        
          | 
            
              PL3326649T3
              (pl)
            
            
            
           | 
          2012-05-03 | 
          2022-04-25 | 
          Boehringer Ingelheim International Gmbh | 
          Przeciwciała anty-il-23p19 
        | 
        
        
          | 
            
              US20140004131A1
              (en)
            
            
            
           | 
          2012-05-04 | 
          2014-01-02 | 
          Novartis Ag | 
          Antibody formulation 
        | 
        
        
          | 
            
              EP2866833B1
              (en)
            
            
            
           | 
          2012-06-27 | 
          2019-05-15 | 
          Merck Sharp & Dohme Corp. | 
          Crystalline anti-human il-23 antibodies 
        | 
        
        
          | 
            
              KR102090849B1
              (ko)
            
            
            
           | 
          2012-07-04 | 
          2020-03-19 | 
          에프. 호프만-라 로슈 아게 | 
          공유 결합된 항원-항체 접합체 
        | 
        
        
          | 
            
              FR2994390B1
              (fr)
            
            
            
           | 
          2012-08-10 | 
          2014-08-15 | 
          Adocia | 
          Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee 
        | 
        
        
          | 
            
              US20140227250A1
              (en)
            
            
            
           | 
          2012-08-23 | 
          2014-08-14 | 
          Merck Sharp & Dohme Corp. | 
          Stable formulations of antibodies to tslp 
        | 
        
        
          | 
            
              US9592297B2
              (en)
            
            
            
           | 
          2012-08-31 | 
          2017-03-14 | 
          Bayer Healthcare Llc | 
          Antibody and protein formulations 
        | 
        
        
          | 
            
              US8883979B2
              (en)
            
            
            
           | 
          2012-08-31 | 
          2014-11-11 | 
          Bayer Healthcare Llc | 
          Anti-prolactin receptor antibody formulations 
        | 
        
        
          | 
            
              EP2919812A4
              (en)
            
            
            
           | 
          2012-11-19 | 
          2016-05-18 | 
          Merck Sharp & Dohme | 
          
        Liquid formulations for TNFR: FC fusion proteins
       
        | 
        
        
          | 
            
              WO2014093206A1
              (en)
            
            
            
           | 
          2012-12-13 | 
          2014-06-19 | 
          Merck Sharp & Dohme Corp. | 
          Lyophilized spherical pellets of anti-il-23 antibodies 
        | 
        
        
          | 
            
              US9700633B2
              (en)
            
            
            
           | 
          2013-01-28 | 
          2017-07-11 | 
          Jenkem Technology Co., Ltd., Tianjin Branch | 
          Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof 
        | 
        
        
          | 
            
              EA201591710A1
              (ru)
            
            
            
           | 
          2013-03-13 | 
          2016-03-31 | 
          Сиэтл Дженетикс, Инк. | 
          Композиции, содержащие циклодекстрин и конъюгат антитело-лекарственное средство 
        | 
        
        
          | 
            
              PL3024484T3
              (pl)
            
            
            
           | 
          2013-07-23 | 
          2018-11-30 | 
          Novaliq Gmbh | 
          Stabilizowane kompozycje przeciwciał 
        | 
        
        
          | 
            
              TWI649308B
              (zh)
            
            
            
           | 
          2013-07-24 | 
          2019-02-01 | 
          小野藥品工業股份有限公司 | 
          喹啉衍生物 
        | 
        
        
          | 
            
              IL312865B2
              (en)
            
            
            
           | 
          2013-09-11 | 
          2025-06-01 | 
          Eagle Biologics Inc | 
          Liquid protein formulations containing viscosity-lowering agents 
      | 
        
        
          | 
            
              BR122023024195A2
              (pt)
            
            
            
           | 
          2013-09-20 | 
          2023-12-26 | 
          Bristol-Myers Squibb Company | 
          Usos de anticorpos anti-lag-3 e anticorpos anti-pd-1 
        | 
        
        
          | 
            
              US9782470B2
              (en)
            
            
            
           | 
          2013-10-16 | 
          2017-10-10 | 
          Merck Sharp & Dohme Corp. | 
          Method of obtaining thermostable dried vaccine formulations 
        | 
        
        
          | 
            
              RU2589691C2
              (ru)
            
            
            
           | 
          2014-06-16 | 
          2016-07-10 | 
          Общество с ограниченной ответственностью "Промоген-МАТ" | 
          Стабильная композиция антитела, специфически связывающегося с her2 рецепторами, и способ ее получения 
        | 
        
        
          | 
            
              WO2015196091A1
              (en)
            
            
            
           | 
          2014-06-20 | 
          2015-12-23 | 
          Reform Biologics, Llc | 
          Viscosity-reducing excipient compounds for protein formulations 
        | 
        
        
          | 
            
              US9907849B2
              (en)
            
            
            
           | 
          2014-07-18 | 
          2018-03-06 | 
          Advaxis, Inc. | 
          Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancer 
        | 
        
        
          | 
            
              CN105296433B
              (zh)
            
            
            
           | 
          2014-08-01 | 
          2018-02-09 | 
          中山康方生物医药有限公司 | 
          一种ctla4抗体、其药物组合物及其用途 
        | 
        
        
          | 
            
              DK3179992T3
              (da)
            
            
            
           | 
          2014-08-11 | 
          2022-07-11 | 
          Acerta Pharma Bv | 
          Terapeutisk kombination af en btk-inhibitor, en pd-1-inhibitor og/eller en pd-l1-inhibitor 
        | 
        
        
          | 
            
              MD4733C1
              (ro)
            
            
            
           | 
          2014-08-19 | 
          2021-07-31 | 
          Merck Sharp & Dohme Corp | 
          Anticorpi anti-TIGIT 
        | 
        
        
          | 
            
              JO3663B1
              (ar)
            
            
            
           | 
          2014-08-19 | 
          2020-08-27 | 
          Merck Sharp & Dohme | 
          الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين 
        | 
        
        
          | 
            
              EP3186281B1
              (en)
            
            
            
           | 
          2014-08-28 | 
          2019-04-10 | 
          Halozyme, Inc. | 
          Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor 
        | 
        
        
          | 
            
              WO2016035006A1
              (en)
            
            
            
           | 
          2014-09-01 | 
          2016-03-10 | 
          Dr. Reddy’S Laboratories Limited | 
          Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir 
        | 
        
        
          | 
            
              CA2967368A1
              (en)
            
            
            
           | 
          2014-11-17 | 
          2016-05-26 | 
          Genentech, Inc. | 
          Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists 
        | 
        
        
          | 
            
              US20170340733A1
              (en)
            
            
            
           | 
          2014-12-19 | 
          2017-11-30 | 
          Novartis Ag | 
          Combination therapies 
      | 
        
        
          | 
            
              US20170360929A1
              (en)
            
            
            
           | 
          2014-12-23 | 
          2017-12-21 | 
          Pfizer Inc. | 
          Stable aqueous antibody formulation for anti tnf alpha antibodies 
      | 
        
        
          | 
            
              KR102644115B1
              (ko)
            
            
            
           | 
          2014-12-23 | 
          2024-03-05 | 
          브리스톨-마이어스 스큅 컴퍼니 | 
          Tigit에 대한 항체 
        | 
        
        
          | 
            
              EP3247408A4
              (en)
            
            
            
           | 
          2015-01-20 | 
          2018-08-22 | 
          Immunexcite, Inc. | 
          Compositions and methods for cancer immunotherapy 
        | 
        
        
          | 
            
              AR103726A1
              (es)
            
            
            
           | 
          2015-02-27 | 
          2017-05-31 | 
          Merck Sharp & Dohme | 
          Cristales de anticuerpos monoclonales anti-pd-1 humanos 
        | 
        
        
          | 
            
              WO2016140717A1
              (en)
            
            
            
           | 
          2015-03-04 | 
          2016-09-09 | 
          Merck Sharp & Dohme Corp. | 
          Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer 
        | 
        
        
          | 
            
              US20180044418A1
              (en)
            
            
            
           | 
          2015-03-20 | 
          2018-02-15 | 
          Merck Sharp & Dohme Corp. | 
          Combination of a pd-1 antagonist and vorinostat for treating cancer 
      | 
        
        
          | 
            
              CN108136001B
              (zh)
            
            
            
           | 
          2015-04-03 | 
          2022-07-29 | 
          佐马技术有限公司 | 
          使用TGF-β抑制剂和PD-1抑制剂治疗癌症 
        | 
        
        
          | 
            
              PE20180394A1
              (es)
            
            
            
           | 
          2015-04-17 | 
          2018-02-28 | 
          Bristol Myers Squibb Co | 
          Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo 
        | 
        
        
          | 
            
              KR20170140316A
              (ko)
            
            
            
           | 
          2015-04-28 | 
          2017-12-20 | 
          브리스톨-마이어스 스큅 컴퍼니 | 
          항-pd-1 항체를 사용한 pd-l1-양성 흑색종의 치료 
        | 
        
        
          | 
            
              ES2985394T3
              (es)
            
            *
            
           | 
          2015-05-29 | 
          2024-11-05 | 
          Merck Sharp & Dohme Llc | 
          Combinación de un antagonista de PD-1 y un oligonucleótido de tipo CpG-C para el tratamiento del cáncer 
        | 
        
        
          | 
            
              TWI773646B
              (zh)
            
            
            
           | 
          2015-06-08 | 
          2022-08-11 | 
          美商宏觀基因股份有限公司 | 
          結合lag-3的分子和其使用方法 
        | 
        
        
          | 
            
              CN114853891A
              (zh)
            
            
            
           | 
          2015-07-22 | 
          2022-08-05 | 
          索伦托药业有限公司 | 
          与lag3结合的抗体治疗剂 
        | 
        
        
          | 
            
              WO2017025498A1
              (en)
            
            *
            
           | 
          2015-08-07 | 
          2017-02-16 | 
          Pieris Pharmaceuticals Gmbh | 
          Novel fusion polypeptide specific for lag-3 and pd-1 
        | 
        
        
          | 
            
              AU2016307845B2
              (en)
            
            
            
           | 
          2015-08-14 | 
          2020-10-15 | 
          Merck Sharp & Dohme Llc | 
          Anti-TIGIT antibodies 
        | 
        
        
          | 
            
              WO2017040864A1
              (en)
            
            
            
           | 
          2015-09-01 | 
          2017-03-09 | 
          First Wave Biopharma | 
          Methods and compositions for treating conditions associated with an abnormal inflammatory responses 
        | 
        
        
          | 
            
              CN117510633A
              (zh)
            
            
            
           | 
          2015-09-02 | 
          2024-02-06 | 
          伊缪泰普有限公司 | 
          抗lag-3抗体 
        | 
        
        
          | 
            
              US20180251548A1
              (en)
            
            
            
           | 
          2015-09-14 | 
          2018-09-06 | 
          Compass Therapeutics Llc | 
          Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-beta 
        | 
        
        
          | 
            
              US9995753B2
              (en)
            
            
            
           | 
          2015-09-25 | 
          2018-06-12 | 
          Merck Sharp & Dohme Corp. | 
          Anti-pembrolizumab antibodies 
        | 
        
        
          | 
            
              US20170097333A1
              (en)
            
            
            
           | 
          2015-09-28 | 
          2017-04-06 | 
          Merck Sharp & Dohme Corp. | 
          Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents 
      | 
        
        
          | 
            
              MX395336B
              (es)
            
            
            
           | 
          2015-09-28 | 
          2025-03-25 | 
          Suzhou Suncadia Biopharmaceuticals Co Ltd | 
          Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina. 
        | 
        
        
          | 
            
              DK3356413T3
              (da)
            
            
            
           | 
          2015-10-01 | 
          2022-04-11 | 
          Potenza Therapeutics Inc | 
          Anti-tigit-antigenbindingsproteiner og fremgangsmåder til anvendelse deraf 
        | 
        
        
          | 
            
              US11034765B2
              (en)
            
            
            
           | 
          2015-10-02 | 
          2021-06-15 | 
          Symphogen A/S | 
          Anti-PD-1 antibodies and compositions 
        | 
        
        
          | 
            
              JO3555B1
              (ar)
            
            
            
           | 
          2015-10-29 | 
          2020-07-05 | 
          Merck Sharp & Dohme | 
          جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري 
        | 
        
        
          | 
            
              ES2862425T3
              (es)
            
            
            
           | 
          2015-11-03 | 
          2021-10-07 | 
          Janssen Biotech Inc | 
          Formulaciones subcutáneas de anticuerpos anti-CD38 y sus usos 
        | 
        
        
          | 
            
              US20190010224A1
              (en)
            
            *
            
           | 
          2015-12-22 | 
          2019-01-10 | 
          Merck Sharp & Dohme Corp. | 
          Formulations of engineered anti-il-10 antibodies 
      | 
        
        
          | 
            
              DK3405490T3
              (da)
            
            
            
           | 
          2016-01-21 | 
          2022-01-10 | 
          Pfizer | 
          Mono- og bispecifikke antistoffer mod epidermal vækstfaktorreceptor variant iii og cd3 og anvendelser deraf 
        | 
        
        
          | 
            
              AR107483A1
              (es)
            
            
            
           | 
          2016-01-29 | 
          2018-05-02 | 
          Hanmi Pharm Ind Co Ltd | 
          Conjugado de enzimas terapéuticas 
        | 
        
        
          | 
            
              HUE053452T2
              (hu)
            
            *
            
           | 
          2016-05-18 | 
          2021-07-28 | 
          Boehringer Ingelheim Int | 
          Anti-PD-1 és anti-LAG3 antitestek rák kezelésére 
        | 
        
        
          | 
            
              HUE068801T2
              (hu)
            
            
            
           | 
          2016-06-14 | 
          2025-01-28 | 
          Xencor Inc | 
          Bispecifikus kontrollpont-gátló antitestek 
        | 
        
        
          | 
            
              WO2018091729A2
              (en)
            
            
            
           | 
          2016-11-21 | 
          2018-05-24 | 
          Zaklady Farmaceutyczne Polpharma Sa | 
          Aqueous pharmaceutical formulations 
        | 
        
        
          | 
            
              RS63533B1
              (sr)
            
            
            
           | 
          2016-12-23 | 
          2022-09-30 | 
          Serum Institute Of India Pvt Ltd | 
          Postupci za povećanje produktivnosti antitela u kulturi sisarskih ćelija i smanjenje agregacije tokom nishodne obrade, postupci formulacije i rezultujuće stabilne formulacije antitela 
        | 
        
        
          | 
            
              TWI761453B
              (zh)
            
            
            
           | 
          2017-03-01 | 
          2022-04-21 | 
          英商梅迪繆思有限公司 | 
          抗rsv單株抗體配製物 
        | 
        
        
          | 
            
              CN112057419B
              (zh)
            
            
            
           | 
          2017-03-01 | 
          2023-08-22 | 
          免疫医疗有限公司 | 
          单克隆抗体的配制品 
        | 
        
        
          | 
            
              AU2018243754B2
              (en)
            
            
            
           | 
          2017-03-31 | 
          2025-04-10 | 
          Bristol-Myers Squibb Company | 
          Methods of treating tumor 
        | 
        
        
          | 
            
              US11603407B2
              (en)
            
            
            
           | 
          2017-04-06 | 
          2023-03-14 | 
          Regeneron Pharmaceuticals, Inc. | 
          Stable antibody formulation 
        | 
        
        
          | 
            
              JOP20190260A1
              (ar)
            
            
            
           | 
          2017-05-02 | 
          2019-10-31 | 
          Merck Sharp & Dohme | 
          صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها 
        | 
        
        
          | 
            
              BR112019022873A8
              (pt)
            
            
            
           | 
          2017-05-02 | 
          2023-04-11 | 
          Merck Sharp & Dohme | 
          Formulação, e, vaso ou dispositivo de injeção. 
        | 
        
        
          | 
            
              EP3618866A4
              (en)
            
            
            
           | 
          2017-05-02 | 
          2021-07-14 | 
          Merck Sharp & Dohme Corp. | 
          
        STABLE FORMULATIONS OF ANTI-CTLA4 ANTIBODIES ALONE AND IN COMBINATION WITH ANTIBODY ANTI-RECEPTOR PROGRAMMED DEATH 1 (PD-1) AND THEIR METHODS OF USE
       
        | 
        
        
          | 
            
              AU2018261080A1
              (en)
            
            
            
           | 
          2017-05-02 | 
          2019-11-07 | 
          Merck Sharp & Dohme Llc | 
          Stable formulations of anti-TIGIT antibodies alone and in combination with programmed death receptor 1 (PD-1) antibodies and methods of use thereof 
      | 
        
        
          | 
            
              CA3065304A1
              (en)
            
            
            
           | 
          2017-05-30 | 
          2018-12-06 | 
          Bristol-Myers Squibb Company | 
          Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody 
      | 
        
        
          | 
            
              DK3631454T3
              (da)
            
            *
            
           | 
          2017-05-30 | 
          2023-12-04 | 
          Bristol Myers Squibb Co | 
          Behandling af lag-3 positive tumorer 
        | 
        
        
          | 
            
              AU2018328015A1
              (en)
            
            
            
           | 
          2017-09-05 | 
          2020-03-05 | 
          Merck Sharp & Dohme Corp. | 
          Compounds for reducing the viscosity of biological formulations 
      | 
        
        
          | 
            
              WO2020022791A1
              (ko)
            
            
            
           | 
          2018-07-25 | 
          2020-01-30 | 
          (주)알테오젠 | 
          신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물 
        | 
        
        
          | 
            
              CA3116592A1
              (en)
            
            
            
           | 
          2018-10-31 | 
          2020-05-07 | 
          Merck Sharp & Dohme Corp. | 
          Anti-human pd-1 antibody crystals and methods of use thereof 
        | 
        
        
          | 
            
              AU2019374748A1
              (en)
            
            
            
           | 
          2018-11-05 | 
          2021-05-27 | 
          Merck Sharp & Dohme Llc | 
          Dosing regimen of anti-LAG3 antibody and combination therapy with anti-PD-1 antibody for treating cancer 
      | 
        
        
          | 
            
              EP3876978A4
              (en)
            
            
            
           | 
          2018-11-07 | 
          2022-09-28 | 
          Merck Sharp & Dohme Corp. | 
          Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof 
        | 
        
        
          | 
            
              JP7503056B6
              (ja)
            
            
            
           | 
          2018-11-07 | 
          2024-07-16 | 
          メルク・シャープ・アンド・ドーム・エルエルシー | 
          抗lag3抗体および抗pd-1抗体の共-製剤 
        | 
        
        
          | 
            
              BR112023005377A2
              (pt)
            
            
            
           | 
          2020-09-24 | 
          2023-04-25 | 
          Merck Sharp & Dohme Llc | 
          Formulações estáveis de anticorpos de receptor de morte programada 1 (pd-1) e variantes de hialuronidase e fragmentos das mesmas e métodos de uso das mesmas 
        |